🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

hi this is a periodic reminder that I also put together BioPharma Dive's Emerging Biotech Weekly newsletter! if you want all the startup news of the week in one place, there's no better place to subscribe. get us to 5,000 readers this week? biopharmadive.com/signup/?signup…

14-1 to withdraw #Makena from the market from #ORUDAC.

FDA advisers back withdrawal of controversial drug for preterm birth biopharmadive.com/news/makena-wi… Jon Gardner

ICYMI: Speedy FDA approvals in focus as agency weighs withdrawal of preterm birth drug biopharmadive.com/news/makena-fd… via BioPharma Dive

An important and overlooked storry since Dobbs v Jackson: ‘I don’t feel safe.’ Abortion bans add new uncertainty to fertility treatment healthcaredive.com/news/ivf-roe-v… via Healthcare Dive

AstraZeneca’s persistence pays off with Imjudo approval biopharmadive.com/news/astrazene… Jon Gardner $AZN $BMY

Contrast. That's what I'm talking about. $BMY

Me, upon learning that one of the new suffixes used for monoclonal antibodies will be "-bart" and wondering what mischief will be made by scientists who are Simpsons fans. #putitdownbart youtube.com/watch?v=gS6F-G…

Is it the bottom of the biotech cycle when companies are getting term loans alongside smallish Big Pharma investments? $KURA

Note to biotech companies and the analysts who cover them: We know what a grade 5 adverse event is. $REGN

It would be an interesting end to the PARP story if it turned out that, like iniparib, none of the PARPs actually inhibited PARP. $AZN $GSK $CLVS $MRK

I love these M&A drawings. $TEVA

Coming out of hibernation (see me at BlueSky!) to look at the $SRPT stream and remind everybody ....